迈克生物 reported revenue of ¥1.03B for the period ended 2026-06-30, -3.8% year on year. Net income was ¥0.03B, a 2.9% net margin on a 57.3% gross margin. The largest revenue line is 自主产品 at 84% of the total. Free cash flow for the period was ¥0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.03B | -3.8% |
| Gross profit | ¥0.59B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.03B | -19.0% |
| Gross margin | 57.3% | Net margin 2.9% |
| Revenue Q/Q | +17.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| 自主产品 | ¥0.87B | 84.0% |
| 代理产品 | ¥0.16B | 15.7% |
| 其他(补充) | ¥0.00B | 0.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.44B | 42.7% |
| R&D | ¥0.14B | 13.8% |
| SG&A | ¥0.40B | 38.3% |
| Tax & other | ¥-0.01B | -1.3% |
| Item | Amount |
|---|---|
| Total assets | ¥7.82B |
| Total liabilities | ¥1.48B |
| Shareholders' equity | ¥6.33B |
| Equity / assets | 81.0% |
| Operating cash flow | ¥0.11B |
| Capital expenditure | ¥0.11B |
| Free cash flow | ¥0.00B |
| Cash conversion (OCF / net income) | 876% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
星徽股份 ・ 高伟达 ・ 赛摩智能 ・ 迅游科技 ・ 四方精创 ・ 信息发展 ・ 中密控股 ・ 厚普股份 ・ *ST新元 ・ 德尔股份 ・ 景嘉微 ・ 香农芯创
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies